However, there is a lack of strong evidence regarding the treatment with biologics (especially for the most recent anti-IL-17 and anti-IL-23 drugs) of patients with concomitant viral hepatitis B or C. These more recent biologics treatments appear to have better safety profiles, based on data from both randomized clinical trials and real-life experiences (16, 21, 17). Here, IL17A is linked to hepatitis B virus infection.